Traws Pharma, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Traws Pharma, Inc. (TRAW) reported Revenue from Contract with Customer, Excluding Assessed Tax of $57.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2024-11-14
- Traws Pharma, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $57.00K, a 0.00% change year-over-year.
- Traws Pharma, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-09-30 was $57.00K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month |
|---|---|---|
| 2024-09-30 | $57.00K 10-Q · filed 2024-11-14 | $170.00K 10-Q · filed 2024-11-14 |
| 2023-09-30 | $57.00K 10-Q · filed 2024-11-14 | $170.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |